此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

深入了解微生物组和环境对镰状细胞病和腿部溃疡研究的贡献(INSIGHTS 研究)

深入了解微生物组和环境对镰状细胞病和腿部溃疡的影响

Background:

- People with sickle cell disease and other blood disorders sometimes get chronic leg ulcers. These are wounds that develop on the skin and don t go away. Current treatments do not work very well, so researchers want to learn more about why the ulcers happen. They want to find out which bacteria may cause it, and if external factors play a role.

Objective:

- To study social and environmental factors of sickle cell disease and the causes of sickle cell disease leg ulcers.

Eligibility:

- People age 18 and older who have sickle cell disease or another red cell disorder, with or without an active leg ulcer.

Design:

  • Participants will have a medical history and clinical evaluation. They will also have blood drawn.
  • Participants will complete questionnaires about their life, health, environment, stress, and other topics.
  • Participants may provide a small sample of hair.
  • Participants will be asked to collect a small amount of saliva.
  • Participants with leg ulcers will have their skin microbiome sampled. The microbiome is all of the microbes (bacteria and and/or fungi) and their genes in and on the body. Researchers will use swabs to collect skin samples. Photographs will be taken of the skin sample area.
  • Some participants without leg ulcers also will have their skin microbiome sampled.
  • Some participants who have their skin microbiome sampled will return for a second visit. At this visit, their microbiome will be resampled. It will take place more than 30 days after the first visit.

研究概览

地位

完全的

详细说明

Study Description:

Leg ulcers are a serious and debilitating complication of sickle cell disease (SCD). This study will explore microbial, genomic, and environmental (social and physical) factors, that may influence the onset and progression of leg ulcer formation and delayed healing in individuals living with SCD. The etiology of SCD-associated leg ulcers is unclear, and we hypothesize that predisposition to developing leg ulcers is multifactorial. This multisite study is an exploratory study of the microbiome and environment of individuals living with sickle cell disease leg ulcers. The study s objective is to identify triggers that may be integral in leg ulcer onset and progression. The central goal of this study is to obtain an improved understanding of the participants clinical phenotype, leg ulcer microbiome and the psychosocial and environmental factors that may impact this complication.

Objectives:

Primary Objective:

Employ genomic approaches to characterize the skin microbiome in individuals living with SCD with and without leg ulcers.

Secondary Objective:

  1. Employ social science research measures to identify psychosocial and physical environmental factors that impact quality of life in individuals living with SCD with and without leg ulcers.
  2. Develop new measure of severity for SCD that integrates clinical outcomes and the quality of life of the participant.
  3. Develop guidelines for researchers to address the needs of diverse and under-resourced groups in genetic research.

Endpoints:

Primary Endpoint:

To characterize the microbiome of leg ulcers in SCD.

Secondary Endpoints:

  1. To characterize the phenotypic variation in SCD.
  2. To identify similarities and differences of the microbial signatures of chronic diabetic foot ulcers and SCD leg ulcers.
  3. To investigate physical and psychosocial environmental indicators that impact quality of life in individuals living with SCD with and without leg ulcers.
  4. To determine if an association exists between the microbiome (microbial diversity) of SCD leg ulcers and the quality of life (psychosocial and physical environment) indicators of individuals with SCD leg ulcers.
  5. To determine if an association exists between the microbiome (microbial diversity) of SCD leg ulcers and clinical phenotype of individuals with SCD leg ulcers.
  6. To determine how leg ulcers influence one s physical function and one s perceptions of stigma and self-esteem.
  7. To identify factors that are indicators of both quality of life and clinical severity of the participant.
  8. To identify specific psychosocial and environmental factors related to resilience in our study population.
  9. To investigate current practices and policies around the return of secondary findings in genome sequencing studies in under-resourced study participant populations, and to explore ethical and clinical policies for returning secondary findings by examining various practices within the research community.
  10. To investigate SCD variation in phenotype, microbiome, physical and psychosocial environments in a cohort in Sierra Leone.
  11. To compare similarities and differences in phenotype, microbiome, physical and psychosocial environments between U.S. and Sierra Leone cohorts.

研究类型

观察性的

注册 (实际的)

405

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Freetown、塞拉利昂
        • University of Sierra Leone, College of Medicine and Allied Health Services
    • Maryland
      • Bethesda、Maryland、美国、20892
        • National Institutes of Health Clinical Center
    • New York
      • The Bronx、New York、美国、10467
        • Montefiore Medical Center/Albert Einstein College of Medicine

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 120年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

取样方法

非概率样本

研究人群

This is a descriptive study of individuals living with sickle cell diseases (SCD) with and without leg ulcers (accrual goal 550 participants). Leg ulcers are not observed in all individuals with SCD and we are interested in understanding why certain individuals develop leg ulcers. We will seek to include age-matched patients without leg ulcers for the microbiome phase of the study. We will recruit and sample male or female adult participants with ulcers, currently without leg ulcers, and those with no previous history of leg ulcers. To ensure we recruit an adequate number of participants with and without leg ulcers, we will rely on multiple recruiting methods, which will include posting flyers, social media advertisements, and/or referrals.

描述

  • INCLUSION CRITERIA:

We will enroll up to four-hundred and fifty (N=450) participants in the microbiome sampling cohort. In addition to the 300 SCD leg ulcer microbiome participants, we will recruit up to an additional 200-250 SCD participants that will complete the clinical evaluation, (including blood sample) and survey instruments for a total of up to 550 participants at three sites, NIH (n=200) and MMC (n=100), and Sierra Leone (n=250).

Of the total participants, we will resample the microbiome of up to 75 individuals from each of the 3 initial sampling groups: SCD with, without and never had SCD leg ulcers. Of those 75 individuals who are sampled longitudinally, those with clinically interesting cases may be sampled at multiple intervals.

All sampling, surveys, and processing of samples will take place at the NIH Clinical Center the second site, MMC, or in Sierra Leone. All samples will be stored at NIH.

To be eligible to participate in this study, an individual must meet all of the following criteria:

  • All subjects must have a diagnosis of sickle cell disease (HbSS, HgSC, HbSB 0 or HBSB+)
  • Be at least 18 years old.
  • Provide written informed consent.
  • For the Qualitative phase: must have a recurrent, active, or single-occurrence presentation of a leg ulcer(s).
  • For the resilience study analysis: cohort will be determined by the research team based on the results of part I of this analysis. For part I, the inclusion criteria are that the individual must have enrolled and completed the INSIGHTS study.

EXCLUSION CRITERIA:

Any individual that meets any of the following criteria during baseline evaluation will be excluded from the study:

  • Pediatric population (<18 years old)
  • Participants for microbiome study (only) who have received oral and/or topical antibiotics or antifungals < 2 weeks prior to enrolling in the study for leg ulcers (for those with leg ulcers only)
  • Subjects presenting with clinically diagnosed bacterial infection (i.e. clinical appearance, clinical judgment, fever, redness around ulcer, purulent drainage etc.) at the site of ulceration. (This can only be diagnosed clinically by the research nurse during sampling

and is only applicable to those with leg ulcers only).

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:CASE_ONLY
  • 时间观点:CROSS_SECTIONAL

队列和干预

团体/队列
Microbiome with active Leg Ulcer

We will recruit and obtain microbiome samples from male or female adult participants with active leg ulcers and sickle cell disease.

Microbiome with no active Leg Ulcer

We will recruit and obtain microbiome samples from male or female adult participants without active leg ulcers but do have sickle cell disease.

Non-microbiome participants

We will recruit but not obtain microbiome samples from participants with sickle cell disease

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
The skin microbiome
大体时间:Assessment occurs on date of visit.

Employ genomic approaches to characterize the skin microbiome in individuals living with SCD with and without leg ulcers

Assessment occurs on date of visit.
The factors that impact quality of life
大体时间:Assessment occurs on date of visit.

Employ social science research measures to identify psychosocial and physical environmental factors that impact quality of life in individuals living with SCD with and without leg ulcers

Assessment occurs on date of visit.
Sickle Cell disease severity measure
大体时间:Assessment occurs on date of visit.

Develop new measure of severity for SCD that integrates clinical outcomes and the quality of life of the participant

Assessment occurs on date of visit.

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Laura M Koehly, Ph.D.、National Human Genome Research Institute (NHGRI)

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2014年6月16日

初级完成 (实际的)

2024年10月1日

研究完成 (实际的)

2024年10月1日

研究注册日期

首次提交

2014年6月4日

首先提交符合 QC 标准的

2014年6月4日

首次发布 (估计的)

2014年6月5日

研究记录更新

最后更新发布 (实际的)

2026年10月29日

上次提交的符合 QC 标准的更新

2026年10月28日

最后验证

2026年9月9日

更多信息

与本研究相关的术语

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅